CSPC Pharmaceutical Group Limited

OTCPK:CHJT.F Stock Report

Market Cap: US$7.2b

CSPC Pharmaceutical Group Management

Management criteria checks 2/4

CSPC Pharmaceutical Group's CEO is Cuilong Zhang, appointed in May 2022, has a tenure of 2.58 years. total yearly compensation is CN¥13.47M, comprised of 5.1% salary and 94.9% bonuses, including company stock and options. directly owns 0.043% of the company’s shares, worth $3.08M. The average tenure of the management team and the board of directors is 1.6 years and 7.8 years respectively.

Key information

Cuilong Zhang

Chief executive officer

CN¥13.5m

Total compensation

CEO salary percentage5.1%
CEO tenure2.6yrs
CEO ownership0.04%
Management average tenure1.6yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Cuilong Zhang's remuneration changed compared to CSPC Pharmaceutical Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥5b

Jun 30 2024n/an/a

CN¥6b

Mar 31 2024n/an/a

CN¥6b

Dec 31 2023CN¥13mCN¥693k

CN¥6b

Sep 30 2023n/an/a

CN¥6b

Jun 30 2023n/an/a

CN¥6b

Mar 31 2023n/an/a

CN¥6b

Dec 31 2022CN¥11mCN¥693k

CN¥6b

Sep 30 2022n/an/a

CN¥6b

Jun 30 2022n/an/a

CN¥6b

Mar 31 2022n/an/a

CN¥6b

Dec 31 2021CN¥9mCN¥693k

CN¥6b

Sep 30 2021n/an/a

CN¥6b

Jun 30 2021n/an/a

CN¥6b

Mar 31 2021n/an/a

CN¥5b

Dec 31 2020CN¥9mCN¥693k

CN¥5b

Sep 30 2020n/an/a

CN¥4b

Jun 30 2020n/an/a

CN¥4b

Mar 31 2020n/an/a

CN¥4b

Dec 31 2019CN¥7mCN¥693k

CN¥4b

Sep 30 2019n/an/a

CN¥4b

Jun 30 2019n/an/a

CN¥3b

Mar 31 2019n/an/a

CN¥3b

Dec 31 2018CN¥4mCN¥298k

CN¥3b

Compensation vs Market: Cuilong's total compensation ($USD1.85M) is below average for companies of similar size in the US market ($USD8.00M).

Compensation vs Earnings: Cuilong's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Cuilong Zhang (55 yo)

2.6yrs

Tenure

CN¥13,472,000

Compensation

Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...

Leadership Team

NamePositionTenureCompensationOwnership
Dongchen Cai
Executive Chairman27.7yrsCN¥26.68m24.23%
$ 1.7b
Cuilong Zhang
Vice-Chairman & CEO2.6yrsCN¥13.47m0.043%
$ 3.1m
Chunlei Li
Executive Director & Chief Scientist7yrsCN¥9.42m0.039%
$ 2.8m
Weidong Pan
Executive Directorno dataCN¥4.92m0.013%
$ 923.8k
Huaiyu Wang
Executive Directorno dataCN¥5.74m0.013%
$ 923.8k
Zhenguo Wang
Executive Directorno dataCN¥4.90m0.013%
$ 923.8k
Xin Cai
Group Executive Presidentno datano datano data
Bing Yao
Executive Directorless than a yearno datano data
Yongjun Liu
Executive president & President of Global Research and Developmentless than a yearno datano data
Weiping Chen
Executive Directorno datano data0.00017%
$ 12.2k
Tai On Lo
Company Secretary3.9yrsno datano data

1.6yrs

Average Tenure

54.5yo

Average Age

Experienced Management: CHJT.F's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Dongchen Cai
Executive Chairman27.7yrsCN¥26.68m24.23%
$ 1.7b
Cuilong Zhang
Vice-Chairman & CEO6.4yrsCN¥13.47m0.043%
$ 3.1m
Chunlei Li
Executive Director & Chief Scientist7yrsCN¥9.42m0.039%
$ 2.8m
Weidong Pan
Executive Director18.2yrsCN¥4.92m0.013%
$ 923.8k
Huaiyu Wang
Executive Director14.2yrsCN¥5.74m0.013%
$ 923.8k
Zhenguo Wang
Executive Director12.9yrsCN¥4.90m0.013%
$ 923.8k
Xin Cai
Group Executive Presidentless than a yearno datano data
Bing Yao
Executive Directorless than a yearno datano data
Weiping Chen
Executive Directorno datano data0.00017%
$ 12.2k
Chun Kwok Au
Independent Non-Executive Director3.9yrsCN¥340.00kno data
Bo Wang
Independent Non-Executive Director12yrsCN¥142.00kno data
Chuan Chen
Independent Non-Executive Director8.5yrsCN¥142.00kno data

7.8yrs

Average Tenure

54.5yo

Average Age

Experienced Board: CHJT.F's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:50
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CSPC Pharmaceutical Group Limited is covered by 50 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Sharon ShiBOCI Research Ltd.
Ethan CuiBofA Global Research